BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083-2091. [PMID: 24604476 DOI: 10.1002/hep.27113] [Cited by in Crossref: 445] [Cited by in F6Publishing: 390] [Article Influence: 63.6] [Reference Citation Analysis]
Number Citing Articles
1 Bae IH, Kim HS, You Y, Chough C, Choe W, Seon MK, Lee SG, Keum G, Jang SK, Moon Kim B. Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. Eur J Med Chem 2015;101:163-78. [PMID: 26134551 DOI: 10.1016/j.ejmech.2015.06.033] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
2 Haga Y, Kanda T, Yasui S, Nakamura M, Ooka Y, Takahashi K, Wu S, Nakamoto S, Arai M, Chiba T, Maruyama H, Yokosuka O, Takada N, Moriyama M, Imazeki F, Kato N. Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature. Oncotarget 2018;9:5509-13. [PMID: 29435197 DOI: 10.18632/oncotarget.23768] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
3 Sato I, Shimbo T, Kawasaki Y, Mizokami M, Masaki N. Efficacy and safety of interferon treatment in elderly patients with chronic hepatitis C in Japan: A retrospective study using the Japanese Interferon Database. Hepatol Res. 2015;45:829-386. [PMID: 25196978 DOI: 10.1111/hepr.12419] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
4 Bunchorntavakul C, Reddy KR. Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2015;42:258-72. [DOI: 10.1111/apt.13264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
5 Hayes CN, Chayama K. Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Rev Clin Pharmacol 2017;10:583-94. [PMID: 28374641 DOI: 10.1080/17512433.2017.1313111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
6 Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y, Aikata H, Abe H, Hayes CN, Sasaki T, Ochi H, Chayama K. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913-1920. [PMID: 25954851 DOI: 10.1002/jmv.24255] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
7 Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, Taunk J, Stern JO, Vinisko R, Gallivan JP, Böcher W, Mensa FJ; SOUND-C3 study group. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. Liver Int 2015;35:417-21. [PMID: 25263751 DOI: 10.1111/liv.12693] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
8 Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N, Shibata S, Ichikawa Y, Komatsu M, Matsumoto A. Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Sci Rep. 2017;7:46705. [PMID: 28425454 DOI: 10.1038/srep46705] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
9 Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, Mcphee F, Hennicken D, Mendez P, Hughes E, Noviello S. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. Journal of Hepatology 2015;63:30-7. [DOI: 10.1016/j.jhep.2015.02.018] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
10 Morishita A, Yoneyama H, Iwama H, Fujita K, Watanabe M, Hirose K, Tadokoro T, Oura K, Sakamoto T, Mimura S, Nomura T, Oryu M, Himoto T, Shimotohno K, Masaki T. Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir. Oncotarget 2018;9:32054-62. [PMID: 30174796 DOI: 10.18632/oncotarget.25889] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
11 Morishita A, Ogawa C, Moriya A, Tani J, Yoneyama H, Fujita K, Oryu M, Senoo T, Takaguchi K, Masaki T. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. Hepatol Res 2020;50:557-64. [PMID: 31883211 DOI: 10.1111/hepr.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Kumada H, Suzuki F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Fujiyama S, Ito T, Itoh Y. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol. 2016;31:14-22. [PMID: 26252875 DOI: 10.1111/jgh.13073] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
13 Yamamoto H, Ikesue H, Ikemura M, Miura R, Fujita K, Chung H, Suginoshita Y, Inokuma T, Hashida T. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci 2018;4:17. [PMID: 30026959 DOI: 10.1186/s40780-018-0113-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mashiba T, Joko K, Kurosaki M, Ochi H, Hasebe C, Akahane T, Sohda T, Tsuji K, Mitsuda A, Kimura H, Narita R, Ogawa C, Furuta K, Shigeno M, Okushin H, Ito H, Kusakabe A, Satou T, Kawanami C, Nakata R, Kobashi H, Tamada T, Ide Y, Yagisawa H, Morita A, Matsushita T, Okada K, Izumi N. Real-world efficacy of elbasvir and grazoprevir for hepatitis C virus (genotype 1): A nationwide, multicenter study by the Japanese Red Cross Hospital Liver Study Group. Hepatol Res 2019;49:1114-20. [PMID: 31077527 DOI: 10.1111/hepr.13362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
15 Nam HC, Lee HL, Yang H, Song MJ. Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection. Clin Mol Hepatol 2016;22:259-66. [PMID: 27377910 DOI: 10.3350/cmh.2016.0020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
16 Al Marzooqi SH, Feld JJ. Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver Int 2015;35:1923-33. [PMID: 25939775 DOI: 10.1111/liv.12861] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
17 Morio R, Imamura M, Kawakami Y, Morio K, Kobayashi T, Yokoyama S, Kimura Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Nelson Hayes C, Aikata H, Takahashi S, Miki D, Ochi H, Mori N, Takaki S, Tsuji K, Chayama K. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. J Gastroenterol 2017;52:504-11. [DOI: 10.1007/s00535-016-1255-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
18 Sagnelli E, Starace M, Minichini C, Pisaturo M, Macera M, Sagnelli C, Coppola N. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection 2018;46:761-83. [DOI: 10.1007/s15010-018-1188-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
19 Santagostino E, Pol S, Olveira A, Reesink HW, van Erpecum K, Bogomolov P, Xu D, Critelli L, Srinivasan S, Cooney E. Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin. Haemophilia 2016;22:692-9. [PMID: 27339614 DOI: 10.1111/hae.12947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yu ML, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL, Chen PJ, Chen DS. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118:556-64. [PMID: 30527566 DOI: 10.1016/j.jfma.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
21 Harada N, Hiramatsu N, Oze T, Tatsumi T, Hayashi N, Takehara T. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma-A retrospective multicenter study: PegIFN/RBV Therapy After HCC Treatment. J Med Virol 2015;87:1199-206. [DOI: 10.1002/jmv.24173] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: A review. J Adv Res. 2015;6:301-310. [PMID: 26257927 DOI: 10.1016/j.jare.2014.11.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
23 Yoshimi S, Ochi H, Murakami E, Uchida T, Kan H, Akamatsu S, Hayes CN, Abe H, Miki D, Hiraga N, Imamura M, Aikata H, Chayama K. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. PLoS One. 2015;10:e0130022. [PMID: 26083687 DOI: 10.1371/journal.pone.0130022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
24 Miyashima Y, Honma Y, Miyagawa K, Oe S, Senju M, Shibata M, Hiura M, Abe S, Harada M. Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder due to Hypersensitivity Reactions. Intern Med 2016;55:3595-601. [PMID: 27980259 DOI: 10.2169/internalmedicine.55.7347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
25 Okubo T, Atsukawa M, Tsubota A, Toyoda H, Shimada N, Abe H, Kato K, Hayama K, Arai T, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kawamoto C, Iio E, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. Hepatol Int 2018;12:133-42. [PMID: 29600429 DOI: 10.1007/s12072-018-9859-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
26 Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis: Daclatasvir plus asunaprevir in non-HD and HD patients. Hepatol Res 2018;48:746-56. [DOI: 10.1111/hepr.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
27 Yoshikawa A, Terashita K, Morikawa K, Matsuda S, Yamamura T, Sarashina K, Nakano S, Kobayashi Y, Sogabe S, Takahashi K, Haba S, Oda H, Takahashi T, Miyagishima T, Sakamoto N. Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report. Clin J Gastroenterol 2017;10:270-3. [PMID: 28447325 DOI: 10.1007/s12328-017-0742-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
28 Morisawa N, Koshima Y, Satoh J, Maruyama Y, Kuriyama S, Yokoo T, Amemiya M. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clin Exp Nephrol 2017;21:818-24. [DOI: 10.1007/s10157-016-1348-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
29 Saito Y, Imamura M, Uchida T, Osawa M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Serikawa M, Aikata H, Abe-Chayama H, Hayes CN, Chayama K. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. J Med Virol 2020;92:210-8. [PMID: 31584207 DOI: 10.1002/jmv.25602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. J Comp Eff Res 2018;7:785-95. [PMID: 29860879 DOI: 10.2217/cer-2018-0005] [Reference Citation Analysis]
31 Sasaki R, Kanda T, Nakamoto S, Haga Y, Nakamura M, Yasui S, Jiang X, Wu S, Arai M, Yokosuka O. Natural interferon-beta treatment for patients with chronic hepatitis C in Japan. World J Hepatol 2015; 7(8): 1125-1132 [PMID: 26052401 DOI: 10.4254/wjh.v7.i8.1125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
32 Tamori A, Enomoto M, Kawada N. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators Inflamm. 2016;2016:6841628. [PMID: 27022210 DOI: 10.1155/2016/6841628] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
33 Yamazaki T, Joshita S, Umemura T, Usami Y, Sugiura A, Fujimori N, Kimura T, Matsumoto A, Igarashi K, Ota M, Tanaka E. Changes in serum levels of autotaxin with direct-acting antiviral therapy in patients with chronic hepatitis C. PLoS One 2018;13:e0195632. [PMID: 29617443 DOI: 10.1371/journal.pone.0195632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ochi H, Aono M, Takechi S, Mashiba T, Yokota T, Joko K. Successful splenorenal shunt occlusion with balloon-occluded retrograde transvenous obliteration yielded improvement of residual liver function, enabled administration of direct-acting antivirals, and achieved sustained virological response to hepatitis C virus: A case report. J Dig Dis 2017;18:125-9. [PMID: 28102583 DOI: 10.1111/1751-2980.12448] [Reference Citation Analysis]
35 Masaki N, Yamagiwa Y, Shimbo T, Murata K, Korenaga M, Kanto T, Mizokami M; prefectural members contributing to the Japanese Interferon Database. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health 2015;15:566. [PMID: 26088426 DOI: 10.1186/s12889-015-1891-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
36 Ogasawara S, Akiba J, Nakayama M, Kusano H, Yano H. Antiproliferative effect of ME3738, a derivative of soyasapogenol, on hepatocellular carcinoma cell lines in vitro and in vivo. Biomed Rep 2016;5:731-6. [PMID: 28105340 DOI: 10.3892/br.2016.792] [Reference Citation Analysis]
37 Nakatsuka K, Atsukawa M, Shimizu M, Takahashi H, Kawamoto C. Ribavirin contributes to eradicate hepatitis C virus through polarization of T helper 1/2 cell balance into T helper 1 dominance. World J Hepatol 2015; 7(25): 2590-2596 [PMID: 26557951 DOI: 10.4254/wjh.v7.i25.2590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
38 Toyota J, Karino Y, Suzuki F, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, Hu W, McPhee F, Linaberry M, Yin PD, Swenson ES, Kumada H. Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection. J Gastroenterol 2017;52:385-95. [PMID: 27502287 DOI: 10.1007/s00535-016-1245-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
39 Kato K, Shimada N, Atsukawa M, Abe H, Itokawa N, Matsumoto Y, Agata R, Tsubota A. Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C. PLoS One 2019;14:e0219022. [PMID: 31291311 DOI: 10.1371/journal.pone.0219022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Obata F, Murakami T, Miyagi J, Ueda S, Inagaki T, Minato M, Ono H, Nishimura K, Shibata E, Tamaki M, Yoshimoto S, Kishi F, Kishi S, Matsuura M, Nagai K, Abe H, Doi T. A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant. CEN Case Rep. 2017;6:55-60. [PMID: 28509128 DOI: 10.1007/s13730-016-0244-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Kan T, Hashimoto S, Kawabe N, Murao M, Nakano T, Shimazaki H, Nakaoka K, Ohki M, Takagawa Y, Kurashita T, Takamura T, Yoshioka K. The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay. J Gastroenterol 2016;51:63-70. [DOI: 10.1007/s00535-015-1080-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
42 Kondo R, Akiba J, Ogasawara S, Nakashima O, Naito Y, Kusano H, Mihara Y, Tanigawa M, Yano H. Programmed death-ligand 1 expression is an unfavorable prognostic factor of hepatocellular carcinoma after archiving sustained virologic response for hepatitis C virus infection. Oncol Lett 2019;18:1458-66. [PMID: 31423211 DOI: 10.3892/ol.2019.10448] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Otsuka T, Kawaguchi Y, Mizuta T, Ide Y, Koga F, Kumagai T, Yoshioka W, Murayama K, Rikitake O, Ikeda Y, Ozaki I. Asunaprevir and daclatasvir in hemodialysis patients with chronic hepatitis C virus genotype 1b infection. JGH Open 2017;1:148-52. [PMID: 30483552 DOI: 10.1002/jgh3.12026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Baba H, Tajiri K, Nagata K, Kawai K, Minemura M, Sugiyama T. Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case Rep Gastroenterol 2016;10:352-9. [PMID: 27504082 DOI: 10.1159/000447486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
45 Hayashi K, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Kawashima H, Ishikawa T, Tachi Y, Hattori M, Katano Y, Goto H, Hirooka Y. Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b: Y93H mutations in hepatitis C virus. Journal of Gastroenterology and Hepatology 2018;33:249-55. [DOI: 10.1111/jgh.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
46 Nagao Y, Kimura K, Kawahigashi Y, Sata M. Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals. Clin Transl Gastroenterol. 2016;7:e179. [PMID: 27388424 DOI: 10.1038/ctg.2016.37] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
47 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K, Goto H, Hirooka Y. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data: DEVTASV in patients with severe fibrosis. Journal of Gastroenterology and Hepatology 2017;32:1879-86. [DOI: 10.1111/jgh.13779] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
48 Ishigami M, Hayashi K, Honda T, Kuzuya T, Ishizu Y, Ishikawa T, Nakano I, Urano F, Kumada T, Yoshioka K. Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93. J Med Virol. 2018;90:736-744. [PMID: 29111616 DOI: 10.1002/jmv.24978] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284-290. [PMID: 27357737 DOI: 10.1002/jmv.24617] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
50 Asahina Y, Izumi N, Hiromitsu K, Kurosaki M, Koike K, Suzuki F, Takikawa H, Tanaka A, Tanaka E, Tanaka Y, Tsubouchi H, Hayashi N, Hiramatsu N, Yotsuyanagi H. JSH Guidelines for the Management of Hepatitis C Virus Infection: A 2016 update for genotype 1 and 2. Hepatol Res 2015;46:129-65. [DOI: 10.1111/hepr.12645] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
51 Cholongitas E, Pipili C, Papatheodoridis G. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J Gastroenterol 2015; 21(32): 9526-9533 [PMID: 26327760 DOI: 10.3748/wjg.v21.i32.9526] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
52 Sohda T, Yamauchi E, Anan A, Yokoyama K, Fukunaga A, Yamauchi R, Fukuda S, Takata K, Tanaka T, Hanano T, Kitamura Y, Morihara D, Takeyama Y, Irie M, Shakado S, Sakisaka S. Non-response to daclatasvir and asunaprevir therapy in patients co-infected with hepatitis C virus genotypes 1 and 2. Hepatol Res 2017;47:364-7. [PMID: 27260815 DOI: 10.1111/hepr.12758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
53 Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F. Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan. Int J Med Sci. 2016;13:418-423. [PMID: 27279790 DOI: 10.7150/ijms.15519] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
54 Misaka K, Kishimoto T, Kawahigashi Y, Sata M, Nagao Y. Use of Direct-Acting Antivirals for the Treatment of Hepatitis C Virus-Associated Oral Lichen Planus: A Case Report. Case Rep Gastroenterol 2016;10:617-22. [PMID: 27920651 DOI: 10.1159/000450679] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
55 Wahid B, Waqar M, Saleem K, Shafi F, Rehman Z, Hanif I, Ahmad HM, Wasim M, Sajjad, Wahid K, Idrees M. Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert ® technology. Future Virology 2018;13:467-74. [DOI: 10.2217/fvl-2017-0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'rear JJ, Naeger LK. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018;67:2430-48. [DOI: 10.1002/hep.29693] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
57 Suda G, Ogawa K, Kimura M, Nakai M, Sho T, Morikawa K, Sakamoto N. Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. J Clin Transl Hepatol 2016;4:320-7. [PMID: 28097101 DOI: 10.14218/JCTH.2016.00032] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
58 Kumada H, Mochida S, Suzuki F, Chayama K, Karino Y, Nakamura K, Fujimoto G, Howe AY, Ludmerer SW, Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies. J Gastroenterol Hepatol 2016;31:1674-83. [PMID: 26936417 DOI: 10.1111/jgh.13328] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
59 Meanwell NA, Belema M. The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. In: Sofia MJ, editor. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing; 2019. pp. 27-55. [DOI: 10.1007/7355_2018_47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Halota W, Flisiak R, Boroń-Kaczmarska A, Juszczyk J, Pawłowska M, Simon K, Tomasiewicz K, Małkowski P; Polish Group of HCV Experts. Recommendations for treatment of hepatitis C. Polish Group of HCV Experts - 2015. Clin Exp Hepatol 2015;1:97-104. [PMID: 28856255 DOI: 10.5114/ceh.2015.55566] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
61 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62:pii: e02217-17. [PMID: 29180522 DOI: 10.1128/aac.02217-17:] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
62 Wu R, Geng D, Chi X, Wang X, Gao X, Xu H, Shi Y, Guan Y, Wang Y, Jin J, Ding Y, Niu J. Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide. Infect Drug Resist. 2019;12:2987-3015. [PMID: 31571951 DOI: 10.2147/idr.s218584] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
63 Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo H, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015;15:645-53. [PMID: 25863559 DOI: 10.1016/S1473-3099(15)70099-X] [Cited by in Crossref: 270] [Cited by in F6Publishing: 130] [Article Influence: 45.0] [Reference Citation Analysis]
64 Osawa M, Ueno T, Shiozaki T, Li H, Garimella T. Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects. J Clin Pharmacol 2019;59:557-65. [PMID: 30566237 DOI: 10.1002/jcph.1347] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
65 Lopez Luis BA, Angulo-Medina L, Rodriguez-Diaz R, Soto-Ramírez LE. Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients With and Without Human Immunodeficiency Virus Coinfection in Mexico. Microb Drug Resist 2021. [PMID: 33794105 DOI: 10.1089/mdr.2020.0436] [Reference Citation Analysis]
66 Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, You CR, Choi SW, Cho SH, Han JY, Song DS, Chang UI, Yang JM, Lee SW, Lee HL, Han NI, Kim SH, Song MJ, Sung PS, Jang JW, Bae SH, Choi JY, Yoon SK. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11. [PMID: 30695109 DOI: 10.1002/jmv.25412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatol Res 2019;49:1275-85. [PMID: 31261439 DOI: 10.1111/hepr.13401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
68 Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
69 Nakamoto S, Kanda T, Shirasawa H, Yokosuka O. Antiviral therapies for chronic hepatitis C virus infection with cirrhosis. World J Hepatol 2015; 7(8): 1133-1141 [PMID: 26052402 DOI: 10.4254/wjh.v7.i8.1133] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
70 Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J Med Virol. 2016;88:506-511. [PMID: 26292191 DOI: 10.1002/jmv.24360] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
71 Kawakami Y, Ochi H, Hayes CN, Imamura M, Tsuge M, Nakahara T, Katamura Y, Kohno H, Kohno H, Tsuji K. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study. J Gastroenterol. 2018;53:548-556. [PMID: 28815329 DOI: 10.1007/s00535-017-1380-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
72 Tarao K, Yamada K. A Hepatitis C Virus-Associated Cirrhotic Patient Developing Interstitial Pneumonia during the Course of Antiviral Therapy with Ombitasvir/Paritaprevir/Ritonavir. Case Rep Gastroenterol 2017;11:369-76. [PMID: 28690490 DOI: 10.1159/000462965] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Eleftheriou P, Amanatidou D, Petrou A, Geronikaki A. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Molecules 2020;25:E2529. [PMID: 32485894 DOI: 10.3390/molecules25112529] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
74 Olson MC, Gardenier D, Jacobson IM. The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. The Journal for Nurse Practitioners 2015;11:116-23. [DOI: 10.1016/j.nurpra.2014.10.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 2019;54:916-27. [PMID: 30903385 DOI: 10.1007/s00535-019-01575-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
76 Teraoka Y, Uchida T, Imamura M, Hiraga N, Osawa M, Kan H, Saito Y, Tsuge M, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure. J Gen Virol 2018;99:1058-65. [PMID: 29916799 DOI: 10.1099/jgv.0.001091] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
77 Takayama H, Sato T, Ikeda F, Fujiki S. Reactivation of hepatitis B virus during interferon-free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co-infection. Hepatol Res. 2016;46:489-491. [PMID: 26297529 DOI: 10.1111/hepr.12578] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 11.5] [Reference Citation Analysis]
78 Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ohdan H, Chayama K. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. Clin J Gastroenterol 2017;10:179-84. [PMID: 28224470 DOI: 10.1007/s12328-017-0722-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C: Ombitasvir/paritaprevir/ritonavir for dialysis patients. Hepatol Res 2017;47:1429-37. [DOI: 10.1111/hepr.12910] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 8.0] [Reference Citation Analysis]
80 Akuta N, Suzuki F, Kobayashi M, Sezaki H, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA. J Clin Microbiol 2015;53:3039-41. [PMID: 26135874 DOI: 10.1128/JCM.01457-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
81 Garimella T, You X, Wang R, Huang SP, Kandoussi H, Bifano M, Bertz R, Eley T. A Review of Daclatasvir Drug-Drug Interactions. Adv Ther. 2016;33:1867-1884. [PMID: 27664109 DOI: 10.1007/s12325-016-0407-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
82 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 5.6] [Reference Citation Analysis]
83 Nakamura M, Kanda T, Haga Y, Sasaki R, Wu S, Nakamoto S, Yasui S, Arai M, Imazeki F, Yokosuka O. Sofosbuvir treatment and hepatitis C virus infection. World J Hepatol 2016; 8(3): 183-190 [PMID: 26839641 DOI: 10.4254/wjh.v8.i3.183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
84 Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Yukimoto A, Hirooka M, Abe M, Hiasa Y. Predictors of hepatocellular carcinoma occurrence after direct-acting antiviral therapy in patients with hepatitis C virus infection. Hepatol Res. 2019;49:136-146. [PMID: 30335208 DOI: 10.1111/hepr.13278] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
85 Orita N, Shimakami T, Sunagozaka H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Takatori H, Kawaguchi K, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation. Clin J Gastroenterol 2019;12:63-70. [PMID: 29995231 DOI: 10.1007/s12328-018-0884-y] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
86 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J Gastroenterol Hepatol 2019;34:364-9. [PMID: 30144366 DOI: 10.1111/jgh.14447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
87 Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Kataoka S, Hashinokuchi S. Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. J Gastroenterol Hepatol. 2017;32:1982-1988. [PMID: 28299813 DOI: 10.1111/jgh.13788] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 23.0] [Reference Citation Analysis]
88 Tanaka T, Akamatsu N, Kaneko J, Arita J, Tamura S, Hasegawa K, Sakamoto Y, Kokudo N. Daclatasvir and asunaprevir for recurrent hepatitis C following living donor liver transplantation with HIV co-infection. Hepatol Res 2016;46:829-32. [PMID: 26508337 DOI: 10.1111/hepr.12614] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mosure KW, Knipe JO, Browning M, Arora V, Shu Y, Phillip T, Mcphee F, Scola P, Balakrishnan A, Soars MG, Santone K, Sinz M. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. Journal of Pharmaceutical Sciences 2015;104:2813-23. [DOI: 10.1002/jps.24356] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
90 Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W. Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis. Intern Med 2018;57:951-6. [PMID: 29225269 DOI: 10.2169/internalmedicine.9671-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
91 Nitta S, Asahina Y, Matsuda M, Yamada N, Sugiyama R, Masaki T, Suzuki R, Kato N, Watanabe M, Wakita T. Effects of Resistance-Associated NS5A Mutations in Hepatitis C Virus on Viral Production and Susceptibility to Antiviral Reagents. Sci Rep. 2016;6:34652. [PMID: 27703205 DOI: 10.1038/srep34652] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
92 Fofiu C, Boeriu A, Coman F, Fofiu A, Panic N, Bulajic M, Dobru D. Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients. Ann Hepatol 2019;18:137-43. [PMID: 31113582 DOI: 10.5604/01.3001.0012.7905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ohashi K, Ishikawa T, Suzuki M, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Hirosawa S, Kobayashi M, Hirosawa H, Sato K, Fukazawa T, Maruyama Y, Yoshida T. Health-related quality of life on the clinical course of patients with chronic hepatitis C receiving daclatasvir/asunaprevir therapy: A prospective observational study comparing younger (<70) and elderly (≥70) patients. Exp Ther Med 2018;15:970-6. [PMID: 29399105 DOI: 10.3892/etm.2017.5488] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2017;47:E120-E131. [PMID: 27142311 DOI: 10.1111/hepr.12738] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
95 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
96 Takeda H, Ueda Y, Inuzuka T, Yamashita Y, Osaki Y, Nasu A, Umeda M, Takemura R, Seno H, Sekine A, Marusawa H. Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing. Sci Rep. 2017;7:45605. [PMID: 28361915 DOI: 10.1038/srep45605] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
97 Kai Y, Hikita H, Tatsumi T, Nakabori T, Saito Y, Morishita N, Tanaka S, Nawa T, Oze T, Sakamori R, Yakushijin T, Hiramatsu N, Suemizu H, Takehara T. Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice. J Gastroenterol. 2015;50:1145-1151. [PMID: 26208695 DOI: 10.1007/s00535-015-1108-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
98 Takaki S, Imamura M, Yamaguchi S, Fukuhara T, Mori N, Tsuji K, Ohya K, Hayes CN, Aikata H, Chayama K. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 2020;13:1233-8. [PMID: 32656649 DOI: 10.1007/s12328-020-01182-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
99 Fukuda H, Yano Y, Sato D, Ohde S, Noto S, Watanabe R, Takahashi O. Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan. Pharmacoeconomics 2020;38:297-306. [PMID: 31761994 DOI: 10.1007/s40273-019-00861-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Tsuji K, Kurosaki M, Itakura J, Mori N, Takaki S, Hasebe C, Akahane T, Joko K, Yagisawa H, Takezawa J, Nakata R, Kusakabe A, Kojima Y, Kimura H, Tamada T, Kobashi H, Mitsuda A, Kondou M, Ogawa C, Uchida Y, Sohda T, Narita R, Izumi N. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Gastroenterol 2018;53:1142-50. [PMID: 29626296 DOI: 10.1007/s00535-018-1455-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
101 Toshikuni N. Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis. Gut Liver 2017;11:335-48. [PMID: 27840363 DOI: 10.5009/gnl15458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
102 Osawa M, Imamura M, Teraoka Y, Uchida T, Morio K, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Chayama K; Hiroshima Liver Study Group. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 2019;54:291-6. [DOI: 10.1007/s00535-018-1520-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
103 Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM; ANRS HC30 QUADRIH Study Group. High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. Clin Infect Dis 2015;61:817-25. [PMID: 25977266 DOI: 10.1093/cid/civ381] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
104 Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016;31:1860-1867. [PMID: 27003037 DOI: 10.1111/jgh.13379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
105 Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. Journal of Hepatology 2015;63:554-63. [DOI: 10.1016/j.jhep.2015.03.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
106 Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A replication complex inhibitor with potent clinical effect. J Med Chem. 2014;57:5057-5071. [PMID: 24749835 DOI: 10.1021/jm500335h] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
107 Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res 2018;48:E372-8. [PMID: 28872737 DOI: 10.1111/hepr.12977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
108 Nakajima T, Karino Y, Hige S, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y, Hasegawa T, Toyota J. Factors affecting the recovery of hepatic reserve after sustained virologic response by direct-acting antiviral agents in chronic hepatitis C virus-infected patients. J Gastroenterol Hepatol 2021;36:367-75. [PMID: 32991760 DOI: 10.1111/jgh.15280] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Fujisaki K, Hashiguchi M, Inada Y, Uto H, Hiramine Y, Kure T, Hori T, Taniyama O, Kasai A, Tamai T, Moriuchi A, Ido A. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir. PLoS One 2018;13:e0198642. [PMID: 29856885 DOI: 10.1371/journal.pone.0198642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
110 Ikeda H, Watanabe T, Shimizu H, Hiraishi T, Kaneko R, Baba T, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H. Efficacy of ledipasvir/sofosbuvir with or without ribavirin for 12 weeks in genotype 1b HCV patients previously treated with a nonstructural protein 5A inhibitor-containing regimen. Hepatol Res. 2018;48:802-809. [PMID: 29504692 DOI: 10.1111/hepr.13074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
111 Suda G, Nakai M, Sho T, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Baba M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. Intern Med 2019;58:943-7. [PMID: 30568153 DOI: 10.2169/internalmedicine.2077-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
112 Kao J, Yu M, Peng C, Heo J, Chu C, Chang T, Lee Y, Hu T, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, Mcphee F, Hu W, Scott Swenson E, Yin PD, Treitel M. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1: Fixed-dose DCV/ASV/BCV for HCV GT-1. Journal of Gastroenterology and Hepatology 2017;32:1998-2005. [DOI: 10.1111/jgh.13796] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
113 Akuta N, Toyota J, Karino Y, Ikeda F, Ido A, Tanaka K, Takaguchi K, Naganuma A, Tomita E, Chayama K, Fujiyama S, Inada Y, Yoshiji H, Watanabe H, Ishikawa H, McPhee F, Noviello S, Kumada H. Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection. J Gastroenterol 2018;53:1089-97. [PMID: 29500489 DOI: 10.1007/s00535-018-1445-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
114 Degasperi E, Aghemo A, Colombo M. Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 2015;16:2679-88. [DOI: 10.1517/14656566.2015.1109631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
115 Park SJ, Kim AR, Choe WH, Kim JH, Yoo BC, Kwon SY. The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Korean J Gastroenterol 2018;72:197-204. [PMID: 30419644 DOI: 10.4166/kjg.2018.72.4.197] [Reference Citation Analysis]
116 Kao J, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng C, Roberts SK, Lee Y, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int 2016;36:954-62. [DOI: 10.1111/liv.13049] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
117 Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A, Howe AY, Ludmerer SW, Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J Gastroenterol 2016;51:390-403. [PMID: 26403160 DOI: 10.1007/s00535-015-1120-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
118 Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H. Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b. J Med Virol 2018;90:313-9. [DOI: 10.1002/jmv.24950] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
119 Ueda Y, Ikegami T, Akamatsu N, Soyama A, Shinoda M, Goto R, Okajima H, Yoshizumi T, Taketomi A, Kitagawa Y, Eguchi S, Kokudo N, Uemoto S, Maehara Y. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol 2017;52:986-91. [PMID: 28138756 DOI: 10.1007/s00535-017-1310-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
120 Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, Konno J, Kimura M, Kawagishi N, Ohara M. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52:1122-1129. [PMID: 28315983 DOI: 10.1007/s00535-017-1328-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
121 Jafri SM, Gordon SC. The safety of daclatasvir for the treatment of hepatitis C. Expert Opin Drug Saf 2015;14:1787-97. [PMID: 26571362 DOI: 10.1517/14740338.2015.1100603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Maekawa S, Sato M, Kuratomi N, Inoue T, Suzuki Y, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Sato T, Sakamoto M, Murakawa M, Nakagawa M, Asahina Y, Enomoto N. Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C. J Gastroenterol 2018;53:780-6. [PMID: 29094205 DOI: 10.1007/s00535-017-1405-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Hiraoka A, Kumada T, Michitaka K, Toyoda H, Tada T, Ueki H, Kaneto M, Aibiki T, Okudaira T, Kawakami T, Kawamura T, Yamago H, Suga Y, Miyamoto Y, Tomida H, Azemoto N, Mori K, Miyata H, Ninomiya T, Kawasaki H. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31:1031-1036. [PMID: 26647219 DOI: 10.1111/jgh.13250] [Cited by in Crossref: 109] [Cited by in F6Publishing: 110] [Article Influence: 27.3] [Reference Citation Analysis]
124 Toyoda H, Kumada T, Tada T, Yama T, Mizuno K. Significance of day-1 viral response of hepatitis C virus in patients with chronic hepatitis C receiving direct-acting antiviral therapy. J Gastroenterol Hepatol 2018;33:1264-70. [PMID: 29164675 DOI: 10.1111/jgh.14053] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int. 2016;10:702-726. [PMID: 27130427 DOI: 10.1007/s12072-016-9717-6] [Cited by in Crossref: 141] [Cited by in F6Publishing: 136] [Article Influence: 28.2] [Reference Citation Analysis]
126 Nagai K, Ide K, Kawasaki Y, Tanaka-Mizuno S, Seto K, Iwane S, Eguchi Y, Kawakami K. Estimating the cost-effectiveness of screening for hepatitis C virus infection in Japan. Hepatol Res 2020;50:542-56. [PMID: 31899841 DOI: 10.1111/hepr.13478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Iida H, Osaki R, Fujimoto T, Maehira H, Mori H, Kitamura N, Andoh A, Tani M. Interval between hepatocellular carcinoma treatment and interferon-free direct-acting antiviral agents against hepatitis C is necessary to suppress tumor recurrence. Mol Clin Oncol 2019;11:99-105. [PMID: 31289685 DOI: 10.3892/mco.2019.1847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Pawlotsky JM. Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. Gastroenterology 2016;151:70-86. [PMID: 27080301 DOI: 10.1053/j.gastro.2016.04.003] [Cited by in Crossref: 368] [Cited by in F6Publishing: 341] [Article Influence: 73.6] [Reference Citation Analysis]
129 Hino N, Sasaki R, Takahashi Y, Koike M, Fukushima M, Haraguchi M, Honda T, Miuma S, Ozawa E, Miyaaki H, Ichikawa T, Nakao K. Treatment of Hepatitis C Virus Infection with Direct-acting Antiviral Agents Elevates the Serum Small-dense Low-density Lipoprotein Cholesterol Level. Intern Med 2021;60:191-9. [PMID: 33456023 DOI: 10.2169/internalmedicine.5563-20] [Reference Citation Analysis]
130 Halota W, Flisiak R, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K; Polish Group of Experts for HCV. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol 2017;3:47-55. [PMID: 28856290 DOI: 10.5114/ceh.2017.67782] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
131 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 32.7] [Reference Citation Analysis]
132 Chayama K, Mitsui F, Hayes CN. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection. Expert Rev Gastroenterol Hepatol 2015;9:21-30. [PMID: 25220206 DOI: 10.1586/17474124.2015.960394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
133 Kumada H, Suzuki F, Kamiya N, Orihashi M, Nakayasu Y, Yamada I. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients. Hepatol Res 2017;47:514-21. [PMID: 27062488 DOI: 10.1111/hepr.12722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
134 Hashimoto S, Yatsuhashi H, Abiru S, Yamasaki K, Komori A, Nagaoka S, Saeki A, Uchida S, Bekki S, Kugiyama Y, Nagata K, Nakamura M, Migita K, Nakao K. Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One. 2016;11:e0163644. [PMID: 27680885 DOI: 10.1371/journal.pone.0163644] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 10.4] [Reference Citation Analysis]
135 Nakamura Y, Imamura M, Kawakami Y, Teraoka Y, Daijo K, Honda F, Morio K, Kobayashi T, Nakahara T, Nagaoki Y. Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. J Med Virol. 2017;89:665-671. [PMID: 27602542 DOI: 10.1002/jmv.24679] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
136 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
137 Kawaoka T, Imamura M, Morio K, Nakamura Y, Tsuge M, Nelson Hayes C, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. Hepatol Res 2016;46:707-12. [PMID: 26439054 DOI: 10.1111/hepr.12602] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
138 Hayes CN, Chayama K. Emerging treatments for chronic hepatitis C. J Formos Med Assoc 2015;114:204-15. [PMID: 25300586 DOI: 10.1016/j.jfma.2014.09.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
139 Tarao K, Tanaka K, Nozaki A, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S, Oshige K. Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients. World J Hepatol 2017; 9(11): 544-550 [PMID: 28469810 DOI: 10.4254/wjh.v9.i11.544] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
140 Yoneyama H, Morishita A, Iwama H, Fujita K, Masaki T, Tani J, Tadokoro T, Nomura T, Sakamoto T, Oura K, Takuma K, Nakahara M, Mimura S, Deguchi A, Oryu M, Tsutsui K, Himoto T, Shimotohno K, Wakita T, Kobara H, Masaki T. Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies. J Gastroenterol Hepatol 2021;36:1126-35. [PMID: 32839985 DOI: 10.1111/jgh.15224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Suzuki M, Ishikawa T, Sakuma A, Abe S, Abe H, Koyama F, Nakano T, Ueki A, Noguchi H, Hasegawa E, Yamagata S, Kobayashi M, Ohashi K, Hirosawa H, Fukazawa T, Maruyama Y, Yoshida T. Evaluation of the health-related quality of life using the 36-item short form health survey in patients with chronic hepatitis C receiving pegylated interferon/ribavirin/telaprevir triple treatment. Exp Ther Med 2016;12:3353-8. [PMID: 27882162 DOI: 10.3892/etm.2016.3785] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
142 Kondo C, Atsukawa M, Tsubota A, Shimada N, Abe H, Asano T, Yoshizawa K, Okubo T, Chuganji Y, Aizawa Y, Iio E, Tanaka Y, Iwakiri K. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease: Daclatasvir/asunaprevir for CHC patients with CKD. Hepatol Res 2017;47:1165-73. [DOI: 10.1111/hepr.12879] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
143 Morio K, Imamura M, Kawakami Y, Morio R, Hatooka M, Kan H, Fujino H, Fukuhara T, Kobayashi T, Masaki K, Ono A, Nakahara T, Urabe A, Yokoyama S, Nagaoki Y, Kawaoka T, Hiraga N, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Ochi H, Chayama K; Hiroshima Liver Study Group. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C: ITPA SNP and simeprevir therapy. Hepatol Res 2016;46:1256-63. [DOI: 10.1111/hepr.12681] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
144 Halota W, Flisiak R, Boroń-Kaczmarska A, Juszczyk J, Małkowski P, Pawłowska M, Simon K, Tomasiewicz K; Polish Group of HCV Experts. Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts - 2016. Clin Exp Hepatol 2016;2:27-33. [PMID: 28856269 DOI: 10.5114/ceh.2016.59099] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
145 Sharma SA, Feld JJ. Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015;17:443. [PMID: 25896437 DOI: 10.1007/s11894-015-0443-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
146 Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2019;54:742-51. [DOI: 10.1007/s00535-019-01568-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
147 Reddy KR, Pol S, Thuluvath PJ, Kumada H, Toyota J, Chayama K, Levin J, Lawitz EJ, Gadano A, Ghesquiere W, Gerken G, Brunetto MR, Peng CY, Silva M, Strasser SI, Heo J, McPhee F, Liu Z, Yang R, Linaberry M, Noviello S. Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens. Liver Int 2018;38:821-33. [PMID: 28941023 DOI: 10.1111/liv.13596] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
148 Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, Ibrahim A, Lau GK, Sharma BC, Hamid SS. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int. 2015;9:486-507. [PMID: 25941137 DOI: 10.1007/s12072-015-9630-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
149 Osawa M, Uchida T, Imamura M, Teraoka Y, Fujino H, Nakahara T, Ono A, Murakami E, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Abe-Chayama H, Hayes CN, Makokha GN, Aikata H, Ishida Y, Tateno C, Miyayama Y, Hijikata M, Chayama K. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. J Gen Virol 2019;100:1123-31. [PMID: 31199224 DOI: 10.1099/jgv.0.001268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Mohammad RA, Bulloch MN, Chan J, Deming P, Love B, Smith L, Dong BJ, GI Liver Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:1341-54. [PMID: 25359244 DOI: 10.1002/phar.1512] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
151 Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf 2015;14:1631-46. [PMID: 26329454 DOI: 10.1517/14740338.2015.1084287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
152 Abe T, Oomori S, Obara W. Current Status of Hepatitis C Virus-Infected Maintenance Hemodialysis Patients in Japan. Ther Apher Dial 2018;22:58-60. [PMID: 29071791 DOI: 10.1111/1744-9987.12603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Morimoto N, Miura K, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Murayama K, Hirosawa T, Goka R, Kunitomo N, Nakamura H, Sugimoto H, Isoda N, Yamamoto H. Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment. J Rural Med 2019;14:78-86. [PMID: 31191770 DOI: 10.2185/jrm.2993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
154 Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2016;43:1276-1292. [PMID: 27087015 DOI: 10.1111/apt.13633] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 19.0] [Reference Citation Analysis]
155 Stirnimann G. Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother 2014;15:2609-22. [PMID: 25347030 DOI: 10.1517/14656566.2014.972364] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
156 Lim SG, Aghemo A, Chen PJ, Dan YY, Gane E, Gani R, Gish RG, Guan R, Jia JD, Lim K. Management of hepatitis C virus infection in the Asia-Pacific region: an update. Lancet Gastroenterol Hepatol. 2017;2:52-62. [PMID: 28404015 DOI: 10.1016/s2468-1253(16)30080-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
157 Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 2018;57:911-928. [PMID: 29353349 DOI: 10.1007/s40262-017-0624-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
158 Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution. Clin Pharmacol Drug Dev 2017;6:195-200. [PMID: 28263460 DOI: 10.1002/cpdd.315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
159 . Daclatasvir. Aust Prescr 2015;38:217-9. [PMID: 26843717 DOI: 10.18773/austprescr.2015.077] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. Frontline Gastroenterol 2018;9:262-70. [PMID: 30245788 DOI: 10.1136/flgastro-2018-101017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
161 Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. J Med Virol. 2018;90:109-119. [PMID: 28842997 DOI: 10.1002/jmv.24923] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
162 Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. Hepatol Res 2015;45:1360-2. [PMID: 25704315 DOI: 10.1111/hepr.12509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
163 Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764 [PMID: 26644819 DOI: 10.4254/wjh.v7.i27.2757] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Itakura J, Kurosaki M, Hasebe C, Osaki Y, Joko K, Yagisawa H, Sakita S, Okushin H, Satou T, Hisai H, Abe T, Tsuji K, Tamada T, Kobashi H, Mitsuda A, Ide Y, Ogawa C, Tsuruta S, Takaguchi K, Murakawa M, Asahina Y, Enomoto N, Izumi N. Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One 2016;11:e0165339. [PMID: 27776192 DOI: 10.1371/journal.pone.0165339] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
165 Mücke VT, Mücke MM, Peiffer KH, Weiler N, Welzel TM, Sarrazin C, Zeuzem S, Berger A, Vermehren J. No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort. Aliment Pharmacol Ther 2017;46:432-9. [PMID: 28627791 DOI: 10.1111/apt.14177] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
166 Brayer SW, Reddy KR. Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Rev Gastroenterol Hepatol 2015;9:547-58. [PMID: 25846301 DOI: 10.1586/17474124.2015.1032938] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
167 McPhee F, Ueland J, Vellucci V, Bowden S, Sievert W, Zhou N. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents. Antimicrob Agents Chemother 2019;63:e02205-18. [PMID: 30718256 DOI: 10.1128/AAC.02205-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
168 Uchida T, Hiraga N, Imamura M, Yoshimi S, Kan H, Miyaki E, Tsuge M, Abe H, Hayes C, Aikata H, Ishida Y, Tateno C, Ellis JD, Chayama K. Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice. Virus Research 2016;213:62-8. [DOI: 10.1016/j.virusres.2015.11.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
169 Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. Transplant Proc 2017;49:1634-8. [PMID: 28838454 DOI: 10.1016/j.transproceed.2017.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
170 Jiang H, Kandoussi H, Zeng J, Wang J, Demers R, Eley T, He B, Burrell R, Easter J, Kadiyala P, Pursley J, Cojocaru L, Baker C, Ryan J, Aubry A, Arnold ME. Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2015;107:409-18. [DOI: 10.1016/j.jpba.2015.01.027] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 7.3] [Reference Citation Analysis]
171 Komatsu TE, Hodowanec AC, Colberg-poley AM, Pikis A, Singer ME, O'rear JJ, Donaldson EF. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products. Antiviral Research 2019;169:104549. [DOI: 10.1016/j.antiviral.2019.104549] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
172 Ito J, Suda G, Yamamoto Y, Nagasaka A, Furuya K, Kumagai K, Kikuchi H, Miyagishima T, Kobayashi T, Kimura M, Yamasaki K, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Terashita K, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; for the NORTE Study Group. Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection: Naturally occurring NS5B RAVs in HCV-1b. Hepatol Res 2016;46:1294-303. [DOI: 10.1111/hepr.12685] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
173 Kan H, Imamura M, Uchida T, Hiraga N, Hayes CN, Tsuge M, Abe H, Aikata H, Makokha GN, Chowdhury S, Miki D, Ochi H, Ishida Y, Tateno C, Chayama K. Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing. J Infect Dis 2016;214:1687-94. [DOI: 10.1093/infdis/jiw437] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
174 Sugawara K, Koushima Y, Inao M, Nakayama N, Nagoshi S, Yakabi K, Tamano M, Asabe S, Nishikawa K, Harada Y, Sekine C, Fukuya Y, Funyu J, Hashimoto Y, Mochida S. Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT): AG & RGT trial with telaprevir. Hepatol Res 2015;45:1091-9. [DOI: 10.1111/hepr.12475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
175 Murayama A, Fujiwara K, Yamada N, Shiina M, Aly HH, Masaki T, Muramatsu M, Wakita T, Kato T. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. Antiviral Res 2018;158:161-70. [PMID: 30118732 DOI: 10.1016/j.antiviral.2018.08.008] [Reference Citation Analysis]
176 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan. Hepatol Res 2019;49:369-76. [PMID: 30485638 DOI: 10.1111/hepr.13292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
177 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 118.4] [Reference Citation Analysis]
178 Tamori A, Inoue K, Kagawa T, Takaguchi K, Nouso K, Iwasaki Y, Minami M, Hai H, Enomoto M, Kawada N. Intention‐to‐treat assessment of glecaprevir + pibrentasvir combination therapy for patients with chronic hepatitis C in the real world. Hepatol Res 2019;49:1365-73. [DOI: 10.1111/hepr.13410] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
179 Wei L, Wang FS, Zhang MX, Jia JD, Yakovlev AA, Xie W, Burnevich E, Niu JQ, Jung YJ, Jiang XJ, Xu M, Chen XY, Xie Q, Li J, Hou JL, Tang H, Dou XG, Gandhi Y, Hu WH, McPhee F, Noviello S, Treitel M, Mo L, Deng J. Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection. World J Gastroenterol 2018; 24(12): 1361-1372 [PMID: 29599611 DOI: 10.3748/wjg.v24.i12.1361] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
180 Kumada H, Chayama K, Rodrigues L, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037-1046. [PMID: 26147154 DOI: 10.1002/hep.27972] [Cited by in Crossref: 126] [Cited by in F6Publishing: 109] [Article Influence: 21.0] [Reference Citation Analysis]
181 Ozeki I, Nakajima T, Yamaguchi M, Kimura M, Arakawa T, Kuwata Y, Ohmura T, Sato T, Hige S, Karino Y, Toyota J. Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy. Hepatol Res 2016;46:1162-7. [PMID: 26857426 DOI: 10.1111/hepr.12667] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
182 Suga T, Sato K, Yamazaki Y, Ohyama T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Probable case of drug reaction with eosinophilia and systemic symptom syndrome due to combination therapy with daclatasvir and asunaprevir. World J Clin Cases 2015; 3(12): 1005-1010 [PMID: 26677451 DOI: 10.12998/wjcc.v3.i12.1005] [Reference Citation Analysis]
183 Matsumoto J, San SN, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R, Sanbe R, Yanaka S, Sakaue H, Kato Y, Nakamura H, Yamada H, Ariyoshi N. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. J Hum Genet 2020;65:143-53. [PMID: 31645655 DOI: 10.1038/s10038-019-0685-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
184 Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K. Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study. Hepatol Res 2019;49:125-35. [PMID: 30307682 DOI: 10.1111/hepr.13256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
185 Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, Mochida S, Toyoda H, Yoshiji H, Takaki S, Yatsuzuka N, Yodoya E, Iwasa T, Fujimoto G, Robertson MN, Black S, Caro L, Wahl J. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study. J Gastroenterol 2017;52:520-33. [PMID: 27873094 DOI: 10.1007/s00535-016-1285-y] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 11.6] [Reference Citation Analysis]
186 Ueno T, Osawa M, Imai Y, Ishikawa H, Garimella T. Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection. J Clin Pharmacol 2018;58:1479-88. [PMID: 30063245 DOI: 10.1002/jcph.1262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
187 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
188 Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12:1197-1209. [PMID: 27384079 DOI: 10.1080/17425255.2016.1209484] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
189 Ludmerer SW, Hirano T, Black S, Howe AY, Chang W, Takase A, Nakamura K, Tanaka Y, Kumada H, Hayashi N, Nickle D. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antiviral Res 2016;130:118-29. [PMID: 26947564 DOI: 10.1016/j.antiviral.2016.03.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
190 Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology. 2015;61:400-401. [PMID: 25308083 DOI: 10.1002/hep.27559] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 4.1] [Reference Citation Analysis]
191 Vargas CL, Espinoza MA, Giglio A, Soza A. Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. PLoS One 2015;10:e0141660. [PMID: 26544203 DOI: 10.1371/journal.pone.0141660] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
192 Canini L, Imamura M, Kawakami Y, Uprichard SL, Cotler SJ, Dahari H, Chayama K. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients. PLoS One 2017;12:e0187409. [PMID: 29216198 DOI: 10.1371/journal.pone.0187409] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
193 Li J, Tian W, Gao D, Li Y, Chang Y, Xu J, Zheng J, Sun P. QSAR Studies on Thiazole Derivatives as HCV NS5A Inhibitors via CoMFA and CoMSIA Methods. LDDD 2019;16:453-60. [DOI: 10.2174/1570180815666180702153529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
194 Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 2016;1:97-104. [PMID: 27917405 DOI: 10.1016/S2468-1253(16)30015-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 12.8] [Reference Citation Analysis]
195 Kang IJ, Hsu SJ, Yang HY, Yeh TK, Lee CC, Lee YC, Tian YW, Song JS, Hsu TA, Chao YS, Yueh A, Chern JH. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. J Med Chem 2017;60:228-47. [PMID: 27966956 DOI: 10.1021/acs.jmedchem.6b00962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
196 Nagao Y, Kimura T, Nagao H. Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture. Biomed Rep 2021;14:23. [PMID: 33335729 DOI: 10.3892/br.2020.1399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Osawa M, Ueno T, Ishikawa H, Imai Y, Garimella T. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. J Clin Pharmacol 2018;58:1468-78. [PMID: 30063254 DOI: 10.1002/jcph.1274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
198 Neuman MG, Malnick S, Maor Y, Nanau RM, Melzer E, Ferenci P, Seitz HK, Mueller S, Mell H, Samuel D, Cohen LB, Kharbanda KK, Osna NA, Ganesan M, Thompson KJ, Mckillop IH, Bautista A, Bataller R, French SW. Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology 2015;99:596-610. [DOI: 10.1016/j.yexmp.2015.09.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
199 Kai Y, Hikita H, Morishita N, Murai K, Nakabori T, Iio S, Hagiwara H, Imai Y, Tamura S, Tsutsui S. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep. 2017;7:41660. [PMID: 28134353 DOI: 10.1038/srep41660] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
200 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
201 Ikeda H, Watanabe T, Matsumoto N, Hiraishi T, Nakano H, Noguchi Y, Hattori N, Shigefuku R, Yamashita M, Nakahara K, Matsunaga K, Okuse C, Yotsuyanagi H, Tanaka A, Suzuki M, Itoh F. Daclatasvir and asunaprevir improves health-related quality of life in Japanese patients infected with hepatitis C virus. JGH Open 2018;2:87-92. [PMID: 30483569 DOI: 10.1002/jgh3.12052] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
202 Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36:1433-1441. [PMID: 27009831 DOI: 10.1111/liv.13128] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
203 Sho T, Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Uebayashi M, Terashita K, Kobayashi T, Tsunematsu I, Onodera M, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Kawagishi N, Ohara M, Ono Y, Nakai M, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. Hepatol Res. 2018;48:529-538. [PMID: 29316051 DOI: 10.1111/hepr.13056] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
204 Hirayama T, Ikegami T, Honda A, Miyazaki T, Yara SI, Kohjima M, Nakamuta M, Matsuzaki Y. Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. Intern Med 2018;57:1219-27. [PMID: 29279486 DOI: 10.2169/internalmedicine.9479-17] [Reference Citation Analysis]
205 Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Okuda S, Tsuji N, Imayoshi Y, Yasuda E. Utility of real-time shear wave elastography for assessing liver fibrosis in patients with chronic hepatitis C infection without cirrhosis: Comparison of liver fibrosis indices: Liver fibrosis evaluated using SWE in CHC. Hepatol Res 2015;45:E122-9. [DOI: 10.1111/hepr.12476] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
206 Oh JY, Kim BS, Lee CH, Song JE, Lee HJ, Park JG, Hwang JS, Chung WJ, Jang BK, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Kwak SG. Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world. Korean J Intern Med 2019;34:794-801. [PMID: 29792020 DOI: 10.3904/kjim.2017.368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
207 Sato K, Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S, Kusano M, Yamada M. Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus. World J Clin Cases 2016; 4(3): 88-93 [PMID: 26989674 DOI: 10.12998/wjcc.v4.i3.88] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
208 Kanda T, Moriyama M. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism. World J Gastroenterol 2017; 23(31): 5645-5649 [PMID: 28883690 DOI: 10.3748/wjg.v23.i31.5645] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
209 Hirashima N, Iwase H, Shimada M, Ryuge N, Imamura J, Ikeda H, Tanaka Y, Matsumoto N, Okuse C, Itoh F, Yokomaku Y, Watanabe T. Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clin J Gastroenterol 2017;10:41-6. [PMID: 27766544 DOI: 10.1007/s12328-016-0693-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
210 Masaki N, Kawasaki Y, Nozaki Y, Yanase M. Characteristics of patients aged over 75 years with hepatitis C virus infection treated with direct-acting antivirals in Japan: Evidence based on the nationwide, real-world database in Japan. Hepatol Res 2021;51:417-25. [PMID: 33217105 DOI: 10.1111/hepr.13596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J, Lee K, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 2016;36:635-43. [DOI: 10.1089/jir.2015.0173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
212 Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, Kurosaki M, Izumi N. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015;22:144-150. [PMID: 25338946 DOI: 10.1002/jhbp.171] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
213 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
214 Ji F, Wei B, Yeo YH, Ogawa E, Zou B, Stave CD, Li Z, Dang S, Furusyo N, Cheung RC, Nguyen MH. Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Aliment Pharmacol Ther 2018;47:550-62. [PMID: 29327780 DOI: 10.1111/apt.14507] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 11.7] [Reference Citation Analysis]
215 Nagaoki Y, Imamura M, Nishida Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Fujino H, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Miki D, Hiyama Y, Ochi H, Chayama K, Aikata H. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy: NAGAOKI et al.. J Med Virol 2019;91:650-8. [DOI: 10.1002/jmv.25352] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
216 Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
217 Park W, Jung J, Yang SH, Lee D, Kang HJ. A case with acute-on-chronic liver failure receiving liver transplantation during daclatasvir and asunaprevir therapy in chronic hepatitis C patient. Gastroenterol Rep (Oxf) 2019;7:371-3. [PMID: 31687158 DOI: 10.1093/gastro/goy012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
218 Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study. Clin Mol Hepatol. 2017;23:51-56. [PMID: 28297836 DOI: 10.3350/cmh.2016.0053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
219 Matsumoto N, Ikeda H, Shigefuku R, Hattori N, Watanabe T, Matsunaga K, Hiraishi T, Tamura T, Noguchi Y, Fukuda Y, Ishii T, Okuse C, Sato A, Suzuki M, Itoh F. Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. PLoS One 2016;11:e0151238. [PMID: 26990758 DOI: 10.1371/journal.pone.0151238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
220 Endo D, Satoh K, Shimada N, Hokari A, Aizawa Y. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b. World J Gastroenterol 2017; 23(13): 2355-2364 [PMID: 28428715 DOI: 10.3748/wjg.v23.i13.2355] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
221 Hayes CN, Imamura M, Chayama K. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir. Expert Rev Gastroenterol Hepatol 2017;11:103-13. [PMID: 27936974 DOI: 10.1080/17474124.2017.1270205] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
222 Wang HL, Lu X, Yang X, Xu N. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: Systematic review and meta-analysis. J Gastroenterol Hepatol. 2017;32:45-52. [PMID: 27597318 DOI: 10.1111/jgh.13587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
223 Yu ML. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens. J Gastroenterol Hepatol 2017;32:1436-42. [PMID: 28124463 DOI: 10.1111/jgh.13747] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
224 Kawakami Y, Imamura M, Ikeda H, Suzuki M, Arataki K, Moriishi M, Mori N, Kokoroishi K, Katamura Y, Ezaki T. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study. J Viral Hepat. 2016;23:850-856. [PMID: 27346670 DOI: 10.1111/jvh.12553] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
225 Honda M, Sugawara Y, Watanabe T, Tateyama M, Tanaka M, Uchida K, Kawabata S, Yoshii D, Miura K, Isono K, Hayashida S, Ohya Y, Yamamoto H, Sasaki Y, Inomata Y. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation. Hepatol Res 2017;47:1147-54. [PMID: 28002876 DOI: 10.1111/hepr.12853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
226 Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study. Aliment Pharmacol Ther 2019;49:1230-41. [DOI: 10.1111/apt.15218] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
227 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol. 2016;22:76-139. [PMID: 27044763 DOI: 10.3350/cmh.2016.22.1.76] [Cited by in Crossref: 42] [Cited by in F6Publishing: 52] [Article Influence: 8.4] [Reference Citation Analysis]
228 Shimada M, Nakamura N, Endo T, Yamabe H, Nakamura M, Murakami R, Narita I, Tomita H. Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report. BMC Nephrol. 2017;18:109. [PMID: 28356063 DOI: 10.1186/s12882-017-0534-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
229 Chida T, Kawata K, Ohta K, Matsunaga E, Ito J, Shimoyama S, Yamazaki S, Noritake H, Suzuki T, Suda T, Kobayashi Y. Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b. Gut Liver 2018;12:201-7. [PMID: 29212314 DOI: 10.5009/gnl17179] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
230 Ikeda H, Watanabe T, Okuse C, Matsumoto N, Ishii T, Yamada N, Shigefuku R, Hattori N, Matsunaga K, Nakano H. Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir. J Med Virol. 2017;89:99-105. [PMID: 27329864 DOI: 10.1002/jmv.24608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
231 Kawakubo M, Eguchi Y, Okada M, Iwane S, Oeda S, Otsuka T, Nakashita S, Araki N, Koga A. Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life. Intern Med 2018;57:1959-66. [PMID: 29526929 DOI: 10.2169/internalmedicine.0091-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
232 Wu SF, Tseng CW, Ho YC, Chen YC, Ko PH, He YT, Tseng KC. Regulatory T Cell Function Modulated After Successful Direct-Acting Antiviral Treatment for Chronic Hepatitis C Patients. Dig Dis Sci 2020;65:1385-95. [PMID: 31559553 DOI: 10.1007/s10620-019-05850-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
233 Calvaruso V, Mazzarelli C, Milazzo L, Badia L, Pasulo L, Guaraldi G, Lionetti R, Villa E, Borghi V, Carrai P, Alberti A, Biolato M, Piai G, Persico M, Santantonio T, Felder M, Angelico M, Montalbano M, Mancusi RL, Grieco A, Angeli E, D'Offizi G, Fagiuoli S, Belli L, Verucchi G, Puoti M, Craxì A. Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. Sci Rep 2019;9:585. [PMID: 30679515 DOI: 10.1038/s41598-018-36734-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
234 Morishita N, Sakamori R, Yamada T, Kai Y, Tahata Y, Urabe A, Yamada R, Kodama T, Hikita H, Doi Y, Tamura S, Hagiwara H, Imai Y, Iio S, Tatsumi T, Takehara T. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. PLoS One 2020;15:e0234811. [PMID: 32544182 DOI: 10.1371/journal.pone.0234811] [Reference Citation Analysis]
235 Wang NY, Xu Y, Zuo WQ, Xiao KJ, Liu L, Zeng XX, You XY, Zhang LD, Gao C, Liu ZH, Ye TH, Xia Y, Xiong Y, Song XJ, Lei Q, Peng CT, Tang H, Yang SY, Wei YQ, Yu LT. Discovery of imidazo[2,1-b]thiazole HCV NS4B inhibitors exhibiting synergistic effect with other direct-acting antiviral agents. J Med Chem 2015;58:2764-78. [PMID: 25710739 DOI: 10.1021/jm501934n] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
236 Itakura J, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Itakura Y, Tamaki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Takahashi Y, Maekawa S, Enomoto N, Izumi N. Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. PLoS One 2015;10:e0138060. [PMID: 26368554 DOI: 10.1371/journal.pone.0138060] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
237 Ichikawa T, Miyaaki H, Miuma S, Motoyoshi Y, Narita S, Toda S, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Hori T, Hirata R, Taura N, Nakao K. Carotid Intima-media Thickness and Small Dense Low-density Lipoprotein Cholesterol Increase after One Year of Treatment with Direct-acting Antivirals in Patients with Hepatitis C Virus Infection. Intern Med 2019;58:1209-15. [PMID: 30626818 DOI: 10.2169/internalmedicine.1514-18] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
238 Ide T, Eguchi Y, Harada M, Ishii K, Morita M, Morita Y, Sugiyama G, Fukushima H, Yano Y, Noguchi K. Evaluation of Resistance-Associated Substitutions in NS5A Using Direct Sequence and Cycleave Method and Treatment Outcome with Daclatasvir and Asunaprevir for Chronic Hepatitis C Genotype 1. PLoS One. 2016;11:e0163884. [PMID: 27684567 DOI: 10.1371/journal.pone.0163884pone-d-16-27137] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther. 2016;43:674-696. [PMID: 26787287 DOI: 10.1111/apt.13514] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 19.8] [Reference Citation Analysis]
240 Izumi N, Takehara T, Chayama K, Yatsuhashi H, Takaguchi K, Ide T, Kurosaki M, Ueno Y, Toyoda H, Kakizaki S, Tanaka Y, Kawakami Y, Enomoto H, Ikeda F, Jiang D, De-Oertel S, McNabb BL, Camus G, Stamm LM, Brainard DM, McHutchison JG, Mochida S, Mizokami M. Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 2018;12:356-67. [PMID: 30030720 DOI: 10.1007/s12072-018-9878-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
241 Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F. Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. J Comp Eff Res 2016;5:273-9. [PMID: 26793987 DOI: 10.2217/cer.15.69] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
242 Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics 2015;16:1179-88. [PMID: 26250055 DOI: 10.2217/pgs.15.65] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
243 Miyaaki H, Ichikawa T, Taura N, Miuma S, Honda T, Shibata H, Soyama A, Hidaka M, Takatsuki M, Eguchi S, Nakao K. Impact of Donor and Recipient Single Nucleotide Polymorphisms in Living Liver Donor Transplantation for Hepatitis C. Transplant Proc 2015;47:2916-9. [PMID: 26707313 DOI: 10.1016/j.transproceed.2015.10.044] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
244 Nguyen NH, Nguyen MH. Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. Gastroenterol Clin North Am 2015;44:871-81. [PMID: 26600225 DOI: 10.1016/j.gtc.2015.07.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
245 Hong CM, Liu CJ, Yeh SH, Chen PJ. Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response. J Formos Med Assoc 2017;116:295-9. [PMID: 28034492 DOI: 10.1016/j.jfma.2016.11.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
246 Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection: DAA Reduces Incidence of HCC in Patients With HCV. J Med Virol 2017;89:476-83. [DOI: 10.1002/jmv.24663] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 15.0] [Reference Citation Analysis]
247 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, Irvin M, Xie W, Fu B, Burroughs M. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62. [PMID: 29180522 DOI: 10.1128/aac.02217-17] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
248 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
249 Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. J Clin Pharmacol 2020;60:331-9. [PMID: 31515816 DOI: 10.1002/jcph.1524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
250 Arai J, Ito T, Shimozuma Y, Uchikoshi M, Nakajima Y, Sakaki M, Uozumi S, Kajiwara A, Sugiura I, Otoyama Y, Nozawa H, Kurihara T, Eguchi J, Nomura N, Sakuma D, Sato M, Deguchi Y, Yoshida H. Decreased expression of interferon-stimulated genes in B cells of patients with chronic hepatitis C during interferon-free therapy potentially suggests the eradication of hepatitis C virus in the B cells: A cohort study. Health Sci Rep 2020;3:e176. [PMID: 32685701 DOI: 10.1002/hsr2.176] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
251 Honda K, Seike M, Oribe J, Endo M, Arakawa M, Tokoro M, Iwao M, Mori T, Nishimura J, Takahashi Y, Omori K, Yamashita T, Muro T, Murakami K. Usefulness of semiquantitative PCR-Invader assay for selecting candidates for daclatasvir plus asunaprevir combination therapy among patients with hepatitis C virus genotype 1b. Hepatol Res 2018;48:255-63. [PMID: 29080280 DOI: 10.1111/hepr.12994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
252 Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res 2017;47:1397-407. [PMID: 28239934 DOI: 10.1111/hepr.12882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
253 Kozuka R, Hai H, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N, Tamori A. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat 2018;25:535-42. [PMID: 29274188 DOI: 10.1111/jvh.12850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
254 Yoshida K, Matsuzaki K, Murata M, Yamaguchi T, Suwa K, Okazaki K. Clinico-Pathological Importance of TGF-β/Phospho-Smad Signaling during Human Hepatic Fibrocarcinogenesis. Cancers (Basel) 2018;10:E183. [PMID: 29874844 DOI: 10.3390/cancers10060183] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
255 Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PLoS One 2018;13:e0205600. [PMID: 30308053 DOI: 10.1371/journal.pone.0205600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Toyoda H, Kumada T, Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. Journal of Hepatology 2017;66:521-7. [DOI: 10.1016/j.jhep.2016.11.012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
257 Hayashi N, Nakamuta M, Takehara T, Kumada H, Takase A, Howe AY, Ludmerer SW, Mobashery N. Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. J Gastroenterol. 2016;51:390-403. [PMID: 26403160 DOI: 10.1007/s00535-015-1120-x10.1007/s00535-015-1120-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Tao W, Gan T, Lu J, Zhong J. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals. Antiviral Res 2017;139:18-24. [PMID: 28025084 DOI: 10.1016/j.antiviral.2016.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
259 Yang SS, Kao JH. Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection. Hepatol Int 2016;10:258-66. [PMID: 26542068 DOI: 10.1007/s12072-015-9668-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
260 McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res 2016;46:423-33. [PMID: 26440999 DOI: 10.1111/hepr.12570] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
261 Mendizabal M, Reddy KR. Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories. J Viral Hepat 2017;24:442-53. [DOI: 10.1111/jvh.12681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
262 Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647. [PMID: 25397971 DOI: 10.1371/journal.pone.0112647pone-d-14-33428] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
263 Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virology 2015; 4(3): 178-184 [PMID: 26279979 DOI: 10.5501/wjv.v4.i3.178] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
264 Toyoda H, Kumada T, Tada T, Takaguchi K, Ishikawa T, Tsuji K, Zeniya M, Iio E, Tanaka Y. Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol 2016;51:741-7. [PMID: 26872889 DOI: 10.1007/s00535-016-1174-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 12.6] [Reference Citation Analysis]
265 Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, Kudo M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Kimura M, Ito J, Umemura M, Izumi T, Tsunematsu S, Sato F, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. Hepatol Res 2017;47:1127-36. [PMID: 27943523 DOI: 10.1111/hepr.12851] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
266 Liu CJ, Chen PJ, Chen DS, Tseng TC, Kao JH. Perspectives on dual hepatitis B and C infection in Taiwan. J Formos Med Assoc 2016;115:298-305. [PMID: 26188762 DOI: 10.1016/j.jfma.2015.06.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
267 Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon 2016;16:e41077. [PMID: 27826322 DOI: 10.5812/hepatmon.41077] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
268 Virabhak S, Yasui K, Yamazaki K, Johnson S, Mitchell D, Yuen C, Samp JC, Igarashi A. Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. J Med Econ 2016;19:1144-56. [PMID: 27348464 DOI: 10.1080/13696998.2016.1206908] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
269 Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respir Investig 2016;54:207-10. [PMID: 27108017 DOI: 10.1016/j.resinv.2015.12.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
270 Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M. Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients. Sci Rep 2019;9:5722. [PMID: 30952914 DOI: 10.1038/s41598-019-42114-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
271 Kanda T, Nirei K, Matsumoto N, Higuchi T, Nakamura H, Yamagami H, Matsuoka S, Moriyama M. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b. World J Gastroenterol 2017; 23(46): 8120-8127 [PMID: 29290649 DOI: 10.3748/wjg.v23.i46.8120] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
272 Okushin K, Suzuki R, Tsutsumi T, Okamoto K, Ikeuchi K, Kado A, Minatsuki C, Minami-Kobayashi Y, Satoh N, Ikeda M, Harada S, Enooku K, Fujinaga H, Yotsuyanagi H, Koike K, Moriya K. Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital. BMC Infect Dis 2021;21:399. [PMID: 33931015 DOI: 10.1186/s12879-021-06117-4] [Reference Citation Analysis]
273 McPhee F, Suzuki Y, Toyota J, Karino Y, Chayama K, Kawakami Y, Yu ML, Ahn SH, Ishikawa H, Bhore R. High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms. Adv Ther. 2015;32:637-649. [PMID: 26155891 DOI: 10.1007/s12325-015-0221-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
274 Köklü S, Köksal I, Akarca US, Balkan A, Güner R, Demirezen A, Sahin M, Akhan S, Ozaras R, Idilman R.  Daclatasvir plus asunaprevir dual therapy for chronic HCV genotype 1b infection: results of Turkish early access program. Ann Hepatol 2017;16:71-6. [PMID: 28051795 DOI: 10.5604/16652681.1226817] [Reference Citation Analysis]
275 Takeda H, Takai A, Inuzuka T, Marusawa H. Genetic basis of hepatitis virus-associated hepatocellular carcinoma: Linkage between infection, inflammation, and tumorigenesis. J Gastroenterol. 2017;52:26-38. [PMID: 27714455 DOI: 10.1007/s00535-016-1273-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
276 Nagaoki Y, Imamura M, Aikata H, Daijo K, Teraoka Y, Honda F, Nakamura Y, Hatooka M, Morio R, Morio K. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. PLoS One. 2017;12:e0182710. [PMID: 28797106 DOI: 10.1371/journal.pone.0182710] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
277 Ichikawa T, Miyaaki H, Miuma S, Taura N, Motoyoshi Y, Akahoshi H, Nakamura S, Nakamura J, Takahashi Y, Honda T, Yajima H, Uehara R, Hino N, Narita S, Tanaka H, Sasaki S, Nakao K. Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals: HCV symptoms after antivirals. Hepatol Res 2018;48:E232-9. [DOI: 10.1111/hepr.12974] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
278 Tsuge M, Hiramatsu A, Shinohara F, Nakano N, Nakamura Y, Hatooka M, Morio K, Morio R, Kan H, Fujino H, Uchida T, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Ono A, Nagaoki Y, Miki D, Kawaoka T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Ochi H, Nelson Hayes C, Chayama K. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. Hepatol Res 2016;46:944-8. [PMID: 26613201 DOI: 10.1111/hepr.12629] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
279 Taki S, Tamai H, Ida Y, Shingaki N, Kawashima A, Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M. The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients. Gut Liver 2018;12:86-93. [PMID: 28798288 DOI: 10.5009/gnl17048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
280 Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open 2018;2:300-6. [PMID: 30619941 DOI: 10.1002/jgh3.12088] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
281 Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Sci Rep 2018;8:8818. [PMID: 29892096 DOI: 10.1038/s41598-018-27291-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
282 Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions. Clin Pharmacokinet 2015;54:1205-22. [DOI: 10.1007/s40262-015-0299-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
283 Murata A, Genda T, Ichida T, Amano N, Sato S, Tsuzura H, Sato S, Narita Y, Kanemitsu Y, Shimada Y, Hirano K, Iijima K, Wada R, Nagahara A, Watanabe S. Pretreatment AKR1B10 expression predicts the risk of hepatocellular carcinoma development after hepatitis C virus eradication. World J Gastroenterol 2016; 22(33): 7569-7578 [PMID: 27672277 DOI: 10.3748/wjg.v22.i33.7569] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
284 Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima A, Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus. Gut Liver 2016;10:617-23. [PMID: 26601828 DOI: 10.5009/gnl15193] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
285 Morio K, Imamura M, Kawakami Y, Morio R, Kobayashi T, Yokoyama S, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Makokha GN, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Mori N, Takaki S, Tsuji K, Chayama K. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. J Gastroenterol Hepatol 2017;32:645-50. [PMID: 27513614 DOI: 10.1111/jgh.13511] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
286 Nagao Y, Nakasone K, Maeshiro T, Nishida N, Kimura K, Kawahigashi Y, Tanaka Y, Sata M. Successful Treatment of Oral Lichen Planus with Direct-Acting Antiviral Agents after Liver Transplantation for Hepatitis C Virus-Associated Hepatocellular Carcinoma. Case Rep Gastroenterol. 2017;11:701-710. [PMID: 29430221 DOI: 10.1159/000484132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
287 Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Shibata A, Asada W, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Kurashita T, Takamura T, Yoshioka K. Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C. World J Gastroenterol 2015; 21(35): 10215-10223 [PMID: 26401087 DOI: 10.3748/wjg.v21.i35.10215] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
288 Iio E, Shimada N, Abe H, Atsukawa M, Yoshizawa K, Takaguchi K, Eguchi Y, Nomura H, Kuramitsu T, Kang J, Matsui T, Hirashima N, Tsubota A, Kusakabe A, Hasegawa I, Miyaki T, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol 2017;52:94-103. [DOI: 10.1007/s00535-016-1225-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
289 Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res. 2016;46:1234-1246. [PMID: 26878268 DOI: 10.1111/hepr.12673] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
290 Park SH. [Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1]. Korean J Gastroenterol 2016;67:127-31. [PMID: 26996181 DOI: 10.4166/kjg.2016.67.3.127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Yeh TK, Kang IJ, Hsu TA, Lee YC, Lee CC, Hsu SJ, Tian YW, Yang HY, Chen CT, Chao YS, Yueh A, Chern JH. A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. Eur J Med Chem 2019;167:245-68. [PMID: 30772607 DOI: 10.1016/j.ejmech.2019.02.016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
292 Akuta N, Suzuki F, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Saitoh S, Kobayashi M, Ikeda K, Kumada H. Evolution of simeprevir-resistant variants in virological non-responders infected with HCV genotype 1b. J Med Virol 2015;87:609-18. [PMID: 25655809 DOI: 10.1002/jmv.24113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
293 Arends J, Kracht P, Hoepelman A. Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clinical Microbiology and Infection 2016;22:846-52. [DOI: 10.1016/j.cmi.2016.05.027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
294 Nagao Y. The role of dentists in controlling hepatocellular carcinoma in Japan (Review). Exp Ther Med 2021;21:113. [PMID: 33335576 DOI: 10.3892/etm.2020.9545] [Reference Citation Analysis]
295 Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES, De-Oertel S, Knox S, Brainard DM, Miller MD, Mo H, Sakamoto N, Takehara T, Omata M. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies. J Viral Hepat. 2016;23:780-788. [PMID: 27196675 DOI: 10.1111/jvh.12549] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
296 Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A. Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. J Comp Eff Res. 2015;4:593-605. [PMID: 26159375 DOI: 10.2217/cer.15.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
297 Yatsuhashi H. Past, Present, and Future of Viral Hepatitis C in Japan. Euroasian J Hepatogastroenterol 2016;6:49-51. [PMID: 29201725 DOI: 10.5005/jp-journals-10018-1166] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
298 Srinivasu G, Kumar KN, Thirupathi C, Narayana CL, Murthy CP. Development and Validation of the Chiral HPLC Method for Daclatasvir in Gradient Elution Mode on Amylose-Based Immobilized Chiral Stationary Phase. Chromatographia 2016;79:1457-67. [DOI: 10.1007/s10337-016-3157-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
299 Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One 2014;9:e112647. [PMID: 25397971 DOI: 10.1371/journal.pone.0112647] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
300 Hirotsu Y, Kanda T, Matsumura H, Moriyama M, Yokosuka O, Omata M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol Int. 2015;9:424-430. [PMID: 25791176 DOI: 10.1007/s12072-015-9624-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
301 Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. J Hepatol. 2014;61:S98-S107. [PMID: 25443350 DOI: 10.1016/j.jhep.2014.08.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
302 Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis: Daclatasvir Plus Asunaprevir. Ther Apher Dial 2016;20:462-7. [DOI: 10.1111/1744-9987.12407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
303 Ohkoshi S, Hirono H, Yamagiwa S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther 2015; 6(4): 114-119 [PMID: 26558145 DOI: 10.4292/wjgpt.v6.i4.114] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
304 Dan YY, Lim SG. Hepatitis C: An Eastern Perspective. Gastroenterol Clin North Am. 2015;44:793-805. [PMID: 26600220 DOI: 10.1016/j.gtc.2015.07.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
305 Tsuji S, Uchida Y, Uemura H, Kouyama J, Naiki K, Nakao M, Motoya D, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res 2020;50:512-23. [DOI: 10.1111/hepr.13471] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
306 Suda G, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y, Yamasaki K, Kimura M, Umemura M, Izumi T, Tsunematsu S, Sato F, Terashita K, Nakai M, Horimoto H, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol 2016;51:733-40. [DOI: 10.1007/s00535-016-1162-8] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 16.6] [Reference Citation Analysis]
307 Zhai PB, Qing J, Li B, Zhang LQ, Ma L, Chen L. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo. Acta Pharmacol Sin 2018;39:1746-52. [PMID: 29930277 DOI: 10.1038/s41401-018-0046-2] [Reference Citation Analysis]
308 Aiza-Haddad I, Ballesteros-Amozurrutia A, Borjas-Almaguer OD, Castillo-Barradas M, Castro-Narro G, Chávez-Tapia N, Chirino-Sprung RA, Cisneros-Garza L, Dehesa-Violante M, Flores-Calderón J, Flores-Gaxiola A, García-Juárez I, González-Huezo MS, González-Moreno EI, Higuera-de la Tijera F, Kershenobich-Stalnikowitz D, López-Méndez E, Malé-Velázquez R, Marín-López E, Mata-Marín JA, Méndez-Sánchez N, Monreal-Robles R, Moreno-Alcántar R, Muñoz-Espinosa L, Navarro-Alvarez S, Pavia-Ruz N, Pérez-Ríos AM, Poo-Ramírez JL, Rizo-Robles MT, Sánchez-Ávila JF, Sandoval-Salas R, Torre A, Torres-Ibarra R, Trejo-Estrada R, Velarde-Ruiz Velasco JA, Wolpert-Barraza E, Bosques-Padilla F. The Mexican consensus on the treatment of hepatitis C. Rev Gastroenterol Mex (Engl Ed) 2018;83:275-324. [PMID: 29803325 DOI: 10.1016/j.rgmx.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 2.3] [Reference Citation Analysis]
309 Chayama K, Hayes CN. HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy. Viruses. 2015;7:5328-5342. [PMID: 26473914 DOI: 10.3390/v7102876] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
310 Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H. A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis. Intern Med 2018;57:2511-5. [PMID: 29607961 DOI: 10.2169/internalmedicine.0585-17] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
311 Suda G, Ogawa K, Morikawa K, Sakamoto N. Treatment of hepatitis C in special populations. J Gastroenterol 2018;53:591-605. [PMID: 29299684 DOI: 10.1007/s00535-017-1427-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
312 Kaido T. Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma. Liver Cancer 2016;5:121-7. [PMID: 27386430 DOI: 10.1159/000367749] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
313 Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J. Impact of previously cured hepatocellular carcinoma (HCC) on new development of HCC after eradication of hepatitis C infection with non-interferon-based treatments. Aliment Pharmacol Ther 2018;48:664-70. [DOI: 10.1111/apt.14914] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
314 Sun LQ, Mull E, Zheng B, D'Andrea S, Zhao Q, Wang AX, Sin N, Venables BL, Sit SY, Chen Y, Chen J, Cocuzza A, Bilder DM, Mathur A, Rampulla R, Chen BC, Palani T, Ganesan S, Arunachalam PN, Falk P, Levine S, Chen C, Friborg J, Yu F, Hernandez D, Sheaffer AK, Knipe JO, Han YH, Schartman R, Donoso M, Mosure K, Sinz MW, Zvyaga T, Rajamani R, Kish K, Tredup J, Klei HE, Gao Q, Ng A, Mueller L, Grasela DM, Adams S, Loy J, Levesque PC, Sun H, Shi H, Sun L, Warner W, Li D, Zhu J, Wang YK, Fang H, Cockett MI, Meanwell NA, McPhee F, Scola PM. Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing. J Med Chem 2016;59:8042-60. [PMID: 27564532 DOI: 10.1021/acs.jmedchem.6b00821] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
315 Fujii H, Nishimura T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Sumida Y, Mitsuyoshi H, Yokomizo C, Tanaka S, Ishikawa H, Nishioji K, Kimura H, Takami S, Nagao Y, Takeuchi T, Shima T, Sawa Y, Minami M, Yasui K, Itoh Y. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching. World J Hepatol 2015; 7(28): 2841-2848 [PMID: 26668696 DOI: 10.4254/wjh.v7.i28.2841] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
316 De Clercq E. Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace: Treatment of hepatitis C accelerating. Rev Med Virol 2015;25:254-67. [DOI: 10.1002/rmv.1842] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
317 Ishikawa T, Abe S, Kojima Y, Kojima S, Yoshida T. Discrepant diagnostic results using two genotyping methods in a chronic hepatitis C patient in serogroup 1: Discrepant genotyping HCV results. Hepatol Res 2016;46:354-6. [DOI: 10.1111/hepr.12536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
318 Ward T, Webster S, Mishina S, McEwan P, Wygant G, Wang F. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues. 2017;12:1-6. [PMID: 28648305 DOI: 10.1016/j.vhri.2016.10.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
319 Akamatsu N, Sugawara Y, Kokudo N. Asunaprevir (BMS-650032) for the treatment of hepatitis C virus. Expert Rev Anti Infect Ther 2015;13:1307-17. [PMID: 26414905 DOI: 10.1586/14787210.2015.1091724] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
320 Morio K, Imamura M, Kawakami Y, Nakamura Y, Hatooka M, Morio R, Fujino H, Nakahara T, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN, Miki D, Ochi H, Katamura Y, Arataki K, Moriya T, Ito H, Tsuji K, Kohno H, Waki K, Tamura T, Nakamura T, Chayama K; Hiroshima Liver Study Group. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. J Med Virol 2018;90:1834-40. [PMID: 30016555 DOI: 10.1002/jmv.25267] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
321 Kondo Y, Kogure T, Ninomiya M, Fukuda R, Monma N, Ikeo K, Tanaka Y. The reduction of miR146b-5p in monocytes and T cells could contribute to the immunopathogenesis of hepatitis C virus infection. Sci Rep 2019;9:13393. [PMID: 31527804 DOI: 10.1038/s41598-019-49706-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol 2017;89:91-8. [PMID: 27256744 DOI: 10.1002/jmv.24592] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
323 Deguchi S, Shintani T, Harada K, Okamoto T, Takemura A, Hirata K, Ito K, Takayama K, Mizuguchi H. In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. Hepatol Commun 2021;5:1385-99. [PMID: 34430783 DOI: 10.1002/hep4.1729] [Reference Citation Analysis]
324 Uchida Y, Kouyama J, Naiki K, Sugawara K, Ando S, Nakao M, Motoya D, Inao M, Imai Y, Nakayama N, Mochida S. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol 2016;51:260-70. [DOI: 10.1007/s00535-015-1106-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
325 Izumi N. Efficacy of daclatasvir in hepatitis C virus. Expert Review of Anti-infective Therapy 2014;12:1025-31. [DOI: 10.1586/14787210.2014.942282] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
326 Kao JH, Tung SY, Lee Y, Thongsawat S, Tanwandee T, Sheen IS, Wu JJ, Li H, Brennan BJ, Zhou J. Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. J Gastroenterol Hepatol. 2016;31:1757-1765. [PMID: 26992248 DOI: 10.1111/jgh.13374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
327 Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, Arataki K, Mori N, Tsuji K, Katamura Y, Takaguchi K, Ishikawa T, Tsuji K, Shimada N, Hiraoka A, Yamsaki S, Nakai M, Sho T, Morikawa K, Ogawa K, Kudo M, Nagasaka A, Furuya K, Yamamoto Y, Kato K, Ueno Y, Iio E, Tanaka Y, Kurosaki M, Kumada T, Chayama K, Sakamoto N. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol 2018;53:119-28. [PMID: 28560477 DOI: 10.1007/s00535-017-1353-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
328 Poole RM. Daclatasvir + asunaprevir: first global approval. Drugs. 2014;74:1559-1571. [PMID: 25117197 DOI: 10.1007/s40265-014-0279-4] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 6.5] [Reference Citation Analysis]
329 Miyaki E, Imamura M, Hiraga N, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Kawakami Y, Aikata H, Hayes CN, Chayama K. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. Hepatol Res. 2016;46:758-764. [PMID: 26574180 DOI: 10.1111/hepr.12621] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
330 Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, Mcnally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology 2017;67:224-36. [DOI: 10.1016/j.jhep.2017.03.014] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 21.3] [Reference Citation Analysis]
331 Lim PJ, Gallay PA. Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance. Curr Opin Virol 2014;8:30-7. [PMID: 24879295 DOI: 10.1016/j.coviro.2014.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
332 Venables BL, Sin N, Wang AX, Sun LQ, Tu Y, Hernandez D, Sheaffer A, Lee M, Dunaj C, Zhai G, Barry D, Friborg J, Yu F, Knipe J, Sandquist J, Falk P, Parker D, Good AC, Rajamani R, McPhee F, Meanwell NA, Scola PM. P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. Bioorg Med Chem Lett 2018;28:1853-9. [PMID: 29650290 DOI: 10.1016/j.bmcl.2018.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
333 Yu JH, Lee JI, Lee KS, Kim JK. Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. Virol J 2017;14:164. [PMID: 28836992 DOI: 10.1186/s12985-017-0826-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
334 Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int 2017;37:1325-33. [PMID: 28178397 DOI: 10.1111/liv.13384] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
335 McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value Health Reg Issues 2014;3:136-45. [PMID: 29702919 DOI: 10.1016/j.vhri.2014.04.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
336 Takeda H, Yamashita T, Ueda Y, Sekine A. Exploring the hepatitis C virus genome using single molecule real-time sequencing. World J Gastroenterol 2019; 25(32): 4661-4672 [PMID: 31528092 DOI: 10.3748/wjg.v25.i32.4661] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
337 Janczewska E, Kołek MF, Lorenc B, Klapaczyński J, Tudrujek-Zdunek M, Sitko M, Mazur W, Zarębska-Michaluk D, Buczyńska I, Dybowska D, Czauż-Andrzejuk A, Berak H, Krygier R, Jaroszewicz J, Citko J, Piekarska A, Dobracka B, Socha Ł, Deroń Z, Laurans Ł, Białkowska-Warzecha J, Tronina O, Adamek B, Tomasiewicz K, Simon K, Pawłowska M, Halota W, Flisiak R. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study. World J Gastroenterol 2021; 27(18): 2177-2192 [PMID: 34025072 DOI: 10.3748/wjg.v27.i18.2177] [Reference Citation Analysis]
338 Gentile I, Buonomo AR, Zappulo E, Minei G, Morisco F, Borrelli F, Coppola N, Borgia G. Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Ther Clin Risk Manag. 2014;10:493-504. [PMID: 25061308 DOI: 10.2147/tcrm.s66731] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
339 Suda G, Sakamoto N. Recent advances in the treatment of hepatitis C virus infection for special populations and remaining problems. J Gastroenterol Hepatol 2021;36:1152-8. [PMID: 32667068 DOI: 10.1111/jgh.15189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
340 Kakisaka K, Yoshida Y, Suzuki Y, Sato T, Kuroda H, Miyasaka A, Takikawa Y. Serum markers for mitochondrial dysfunction and cell death are possible predictive indicators for drug-induced liver injury by direct acting antivirals: Prediction of idiosyncratic DILI. Hepatol Res 2018;48:78-86. [DOI: 10.1111/hepr.12893] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
341 Fujii H, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Nakamura H, Yasui K, Minami M, Tanaka S, Ishikawa H, Kimura H, Takami S, Nagao Y, Shima T, Itoh Y. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol 2017; 9(25): 1064-1072 [PMID: 28951778 DOI: 10.4254/wjh.v9.i25.1064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
342 Horner SM, Naggie S. Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog. 2015;11:e1004854. [PMID: 26087286 DOI: 10.1371/journal.ppat.1004854] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
343 Liverton NJ. Evolution of HCV NS3/4a Protease Inhibitors. In: Sofia MJ, editor. HCV: The Journey from Discovery to a Cure. Cham: Springer International Publishing; 2019. pp. 231-59. [DOI: 10.1007/7355_2018_39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
344 Lee HW, Oh SR, Kim DY, Jeong Y, Kim S, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety. Gut Liver 2018;12:324-30. [PMID: 29409309 DOI: 10.5009/gnl17298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
345 Shindoh J, Hashimoto M, Watanabe G. Surgical approach for hepatitis C virus-related hepatocellular carcinoma. World J Hepatol 2015; 7(1): 70-77 [PMID: 25624998 DOI: 10.4254/wjh.v7.i1.70] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
346 Bichoupan K, Dieterich DT. Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs 2014;74:951-61. [PMID: 24866024 DOI: 10.1007/s40265-014-0232-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
347 Simoes P, Asaad A, Abed J, Engelson ES, Kotler DP. Effect of Gender on the Response to Hepatitis C Treatment in an Inner-City Population. Womens Health Issues 2015;25:289-93. [PMID: 25965157 DOI: 10.1016/j.whi.2015.02.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
348 Suzuki F, Hatanaka N, Bando E, Nakamura K, Komoto A. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan. Hepatol Int 2018;12:244-53. [DOI: 10.1007/s12072-018-9872-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
349 Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia. Korean J Intern Med 2015;30:423-33. [PMID: 26161008 DOI: 10.3904/kjim.2015.30.4.423] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
350 Londoño MC, Perelló C, Cabezas J, Cañete N, Lens S, Mariño Z, Gambato M, Rodríguez R, Menéndez S, Carrión JA, Crespo J, Calleja JL, Forns X. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. J Hepatol 2015;62:311-6. [PMID: 25281861 DOI: 10.1016/j.jhep.2014.09.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
351 Esposito I, Marciano S, Trinks J. Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:649-57. [PMID: 29855221 DOI: 10.1080/17425255.2018.1483336] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M. Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System. J Clin Transl Hepatol 2016;4:5-11. [PMID: 27047766 DOI: 10.14218/JCTH.2015.00047] [Reference Citation Analysis]
353 Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C, Chang T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C, Sievert W, Bronowicki J, Thabut D, Lee Y, Kao J, Mcphee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. The Lancet 2014;384:1597-605. [DOI: 10.1016/s0140-6736(14)61059-x] [Cited by in Crossref: 248] [Cited by in F6Publishing: 122] [Article Influence: 35.4] [Reference Citation Analysis]
354 Ohfuji S, Matsuura T, Tamori A, Kubo S, Sasaki S, Kondo K, Ito K, Fukushima W. Lifestyles Associated with Prognosis After Eradication of Hepatitis C Virus: A Prospective Cohort Study in Japan. Dig Dis Sci 2021;66:2118-28. [PMID: 32720018 DOI: 10.1007/s10620-020-06475-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Chayama K, Hayes CN. Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir. J Gastroenterol 2017;52:125-6. [DOI: 10.1007/s00535-016-1252-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
356 Smith MA, Regal RE, Mohammad RA. Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection. Ann Pharmacother 2016;50:39-46. [PMID: 26486762 DOI: 10.1177/1060028015610342] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
357 Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, Tsubota A, Abe H, Kato K, Kusakabe A. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res. 2017;. [PMID: 28332272 DOI: 10.1111/hepr.12898] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
358 Liu YC, Jeng WJ, Cheng YT, Hsieh YC, Teng W, Chen YC, Lin CY, Chien RN, Sheen IS. Incidence and predictors for abnormal liver function during direct-acting antiviral agents in chronic hepatitis C patients. Medicine (Baltimore) 2020;99:e21898. [PMID: 32925725 DOI: 10.1097/MD.0000000000021898] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother. 2015;60:1106-1113. [PMID: 26643326 DOI: 10.1128/aac.02606-15] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
360 Toyoda H, Atsukawa M, Takaguchi K, Senoh T, Michitaka K, Hiraoka A, Fujioka S, Kondo C, Okubo T, Uojima H, Tada T, Yoneyama H, Watanabe T, Asano T, Ishikawa T, Tamai H, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Deguchi A, Itobayashi E, Mikami S, Moriya A, Okubo H, Tani J, Tsubota A, Tanaka Y, Masaki T, Iwakiri K, Kumada T. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan. J Gastroenterol 2018;53:1276-84. [PMID: 29740665 DOI: 10.1007/s00535-018-1473-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
361 Vilchez RA. Hepatitis C virus genotype 1 NS5A variants in Japanese patients. Lancet Infect Dis 2015;15:1378. [PMID: 26607122 DOI: 10.1016/S1473-3099(15)00404-1] [Reference Citation Analysis]
362 Sadler MD, Lee SS. Revolution in hepatitis C antiviral therapy. Br Med Bull. 2015;113:31-44. [PMID: 25680808 DOI: 10.1093/bmb/ldv004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
363 Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately. Intern Med 2021;60:3061-70. [PMID: 34602520 DOI: 10.2169/internalmedicine.6591-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
364 Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
365 Yoshida K, Hai H, Tamori A, Teranishi Y, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y, Kawada N. Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed. Int J Mol Sci 2017;18:E962. [PMID: 28467359 DOI: 10.3390/ijms18050962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
366 Hernandez D, Yu F, Huang X, Kirov S, Pant S, Mcphee F. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Adv Ther 2016;33:1169-79. [DOI: 10.1007/s12325-016-0354-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
367 Kan H, Imamura M, Kawakami Y, Daijo K, Teraoka Y, Honda F, Nakamura Y, Morio K, Kobayashi T, Nakahara T. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. J Med Virol. 2017;89:1963-1972. [PMID: 28657143 DOI: 10.1002/jmv.24885] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
368 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
369 Ozono Y, Nagata K, Hasuike S, Iwakiri H, Nakamura K, Tsuchimochi M, Yamada Y, Takaishi Y, Sueta M, Miike T, Tahara Y, Yamamoto S, Shide K, Hidaka T, Kubuki Y, Kusumoto K, Ochiai T, Kato J, Komada N, Hirono S, Kuroki K, Shigehira M, Shimoda K. Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1. World J Hepatol 2017; 9(36): 1340-1345 [PMID: 29359017 DOI: 10.4254/wjh.v9.i36.1340] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
370 Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, Ikegami T, Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan. Open Forum Infect Dis 2019;6:ofz185. [PMID: 31123693 DOI: 10.1093/ofid/ofz185] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
371 Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res 2018;48:233-43. [PMID: 28884930 DOI: 10.1111/hepr.12980] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
372 Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, Hasegawa K, Sakamoto Y, Kokudo N. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation: DAA for HCV-infected LDLT recipient. Hepatol Res 2017;47:1093-101. [DOI: 10.1111/hepr.12845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
373 Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015; 7(28): 2829-2833 [PMID: 26668694 DOI: 10.4254/wjh.v7.i28.2829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
374 Suda G, Ito J, Nagasaka A, Yamamoto Y, Furuya K, Okamoto M, Terashita K, Kobayashi T, Tsunematsu I, Yoshida J, Meguro T, Ohara M, Kawagishi N, Kimura M, Umemura M, Izumi T, Tsukuda Y, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; for the NORTE Study Group. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study: FLV add-on SMV/Peg-IFN/RBV therapy. Hepatol Res 2018;48:E146-54. [DOI: 10.1111/hepr.12938] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
375 Tamori A, Hai H, Uchida-Kobayashi S, Enomoto M, Kozuka R, Motoyama H, Kawamura E, Hagihara A, Teranishi Y, Yoshida K, Morikawa H, Murakami Y, Kawada N. Outcomes for Cirrhotic Patients with Hepatitis C Virus 1b Treated with Asunaprevir and Daclatasvir Combination. Ann Hepatol 2017;16:734-41. [PMID: 28809743 DOI: 10.5604/01.3001.0010.2732] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
376 Bourlière M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Stamm LM, Zhang J, Dvory-Sobol H, Subramanian GM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, Manns MP. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1. Lancet Gastroenterol Hepatol 2018;3:559-65. [PMID: 29859740 DOI: 10.1016/S2468-1253(18)30118-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
377 Chayama K, Imamura M, Hayes CN. Hepatitis C virus treatment update - A new era of all-oral HCV treatment. Advances in Digestive Medicine 2016;3:153-60. [DOI: 10.1016/j.aidm.2016.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
378 Mawatari S, Oda K, Tabu K, Ijuin S, Kumagai K, Inada Y, Uto H, Hiramine Y, Kure T, Fujisaki K, Hashiguchi M, Hori T, Oshige A, Imanaka D, Saishoji A, Taniyama O, Sakae H, Tamai T, Moriuchi A, Ido A. New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir. J Gastroenterol 2017;52:855-67. [DOI: 10.1007/s00535-016-1303-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
379 Friborg J, Zhou N, Han Z, Yang X, Falk P, Mendez P, McPhee F. In Vitro Assessment of Re-treatment Options for Patients with Hepatitis C Virus Genotype 1b Infection Resistant to Daclatasvir Plus Asunaprevir. Infect Dis Ther 2014. [PMID: 25516102 DOI: 10.1007/s40121-014-0052-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
380 Osawa M, Ueno T, Shiozaki T, Ishikawa H, Li H, Garimella T. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clin Pharmacol Drug Dev 2019;8:802-17. [PMID: 30629858 DOI: 10.1002/cpdd.649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
381 Mawatari S, Oda K, Kumagai K, Tabu K, Ijuin S, Fujisaki K, Inada Y, Uto H, Saisyoji A, Hiramine Y, Hori T, Taniyama O, Toyodome A, Sakae H, Hashiguchi M, Kure T, Sakurai K, Tamai T, Moriuchi A, Ido A. Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy. Hepatol Res 2020;50:453-65. [PMID: 31846553 DOI: 10.1111/hepr.13474] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
382 Sato A, Ishii T, Adachi K, Kumon D, Tamura T, Noguchi Y, Matsumoto N, Okuse C. Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy. Clin J Gastroenterol 2016;9:89-92. [PMID: 26896968 DOI: 10.1007/s12328-016-0630-2] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
383 Mori N, Imamura M, Kawakami Y, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Hayes CN, Aikata H, Miki D, Ochi H, Honda Y, Takaki S, Tsuji K, Chayama K; Hiroshima Liver Study Group. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. Hepatol Res 2017;47:E5-E13. [PMID: 27027531 DOI: 10.1111/hepr.12715] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
384 Uemura H, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Sugawara K, Nakao M, Motoya D, Nakayama N, Imai Y, Tomiya T, Mochida S. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019;54:459-470. [PMID: 30612205 DOI: 10.1007/s00535-018-01543-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 11.0] [Reference Citation Analysis]
385 Okubo T, Atsukawa M, Tsubota A, Shimada N, Abe H, Yoshizawa K, Arai T, Nakagawa A, Itokawa N, Kondo C. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants. Hepatol Res. 2017;47:641-649. [PMID: 27487797 DOI: 10.1111/hepr.12784] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
386 Yang S, Kao J. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 2014;9:9-20. [DOI: 10.1586/17474124.2014.953930] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
387 Ahmed AM, Doheim MF, Mattar OM, Sherif NA, Truong DH, Hoa PTL, Hirayama K, Huy NT. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90:907-18. [PMID: 28892235 DOI: 10.1002/jmv.24947] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
388 Yamashita T, Takeda H, Takai A, Arasawa S, Nakamura F, Mashimo Y, Hozan M, Ohtsuru S, Seno H, Ueda Y, Sekine A. Single-molecular real-time deep sequencing reveals the dynamics of multi-drug resistant haplotypes and structural variations in the hepatitis C virus genome. Sci Rep 2020;10:2651. [PMID: 32060395 DOI: 10.1038/s41598-020-59397-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
389 Umemura T, Yamazaki T, Joshita S, Sugiura A, Fujimori N, Matsumoto A, Ota M, Tanaka E. Quantitative analysis of serum chemokines associated with treatment failure of direct-acting antivirals in chronic hepatitis C. Cytokine 2018;111:357-63. [PMID: 30296712 DOI: 10.1016/j.cyto.2018.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
390 Kaneko R, Nakazaki N, Omori R, Yano Y, Ogawa M, Sato Y. Efficacy of direct-acting antiviral treatment for chronic hepatitis C: A single hospital experience. World J Hepatol 2018; 10(1): 88-94 [PMID: 29399282 DOI: 10.4254/wjh.v10.i1.88] [Reference Citation Analysis]